OLMA Earnings & Financial Statements
Olema Pharmaceuticals, Inc.
$6.80
$0.00(0.00%)
30
Overall
60
Value
9
Tech
21
Quality
Market Cap
$594.98M
Volume
75.31K
52W Range
$6.65 - $36.26
Target Price
$37.30
OLMA earnings and financial statements: Olema Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
OLMA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$178.70M | -$142.26M | -$104.96M | -$106.99M | -$71.49M |
| EBITDA | -$167.08M | -$136.11M | -$101.11M | -$106.63M | -$69.43M |
| Net income | -$162.45M | -$129.47M | -$96.66M | -$104.79M | -$71.10M |
| EPS (diluted) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $533.43M | $450.98M | $276.94M | $215.65M | $295.94M |
| Total liabilities | $54.87M | $42.02M | $23.05M | $18.10M | $11.38M |
| Shareholders’ equity | $478.56M | $408.96M | $253.90M | $197.55M | $284.57M |
| Cash and equivalents | $48.30M | $139.48M | $68.54M | $23.70M | $13.81M |
| Long-term debt | $3.07M | $257.0K | $1.43M | $1.55M | $2.36M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$146.72M | -$104.35M | -$83.73M | -$82.06M | -$50.69M |
| Capital expenditure | - | -$159.0K | - | -$363.0K | -$1.57M |
| Free cash flow | -$146.72M | -$104.51M | -$83.73M | -$82.43M | -$52.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OLMA | $6.80 | 0% | 75.31K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Olema Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW